Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
VH4367310 · 1 trial · 1 indication
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention.
Severity is graded according to the Division of Acquired Immunodeficiency Syndrome (DAIDS) grading criteria, where Grade 1 = mild, Grade 2 = moderate, Grade 3 = severe, Grade 4 = potentially life-threatening, Grade 5 = Death.
An SAE is defined as any untoward medical occurrence that results in death, is life threatening, requires hospitalization or prolongs existing hospitalization, results in disability/incapacity or other medically significant events.
| Arm | Type | Description |
|---|---|---|
| VH4367310 Group | EXPERIMENTAL | Participants will be randomized to receive a single injection of VH4367310 on Day 1. |
| Placebo Group | PLACEBO_COMPARATOR | Participants will be randomized to receive placebo on Day 1. |
| Name | Type | Description |
|---|---|---|
| VH4367310 | DRUG | VH4367310 will be administered intramuscularly. |
| Placebo | DRUG | Placebo will be administered intramuscularly. |
Inclusion Criteria: * Participant must be greater than or equal to (\>=) 18 years and less than or equal to (\<=) 55 years of age, at the time of signing the informed consent. * Participants who are overtly healthy as determined by medical evaluation. * Body weight \>=40 kg and BMI within the range...
Top 19 of 29 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | VLA15, Prevenar 20, 13vPnC, ATM-AVI, PG4 |
| Sanofi SA Sponsored ADR | SNY | 1 | PHASE3 | PCV21 |
| GSK plc Sponsored ADR | GSK | 4 | PHASE2 | Penmenvy, iNTS-TCV, Strep A vaccine, Pan-Salmonella vaccine |
| Grifols, S.A. Sponsored ADR Class B | GRFS | 1 | PHASE3 | Xembify |
| CorMedix Inc. | CRMD | 1 | PHASE3 | DefenCath |
| Sinovac Biotech Ltd. | SVA | 4 | PHASE3 | Sinovac PCV24, Group ACYW135X Meningococcal Conjugate Vaccine, Group ACYW135 Meningococcal Conjugate Vaccine |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | EDI048 |
| Innoviva, Inc. | INVA | 3 | PHASE2 | Eravacycline, Sulbactam-durlobactam |
| BiomX Inc. | PHGE | 1 | PHASE2 | BX004 |
| Hoffmann-La Roche | RHHBY | 1 | PHASE3 | Baloxavir Marboxil |
| Merck & Co., Inc. | MRK | 2 | PHASE1 | V118C |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD7760 |
| BioNTech SE Sponsored ADR | BNTX | 1 | PHASE1 | BNT163 |
| 60 Degrees Pharmaceuticals, Inc. | SXTP | 1 | PHASE2 | Tafenoquine |
| Tarsus Pharmaceuticals, Inc. | TARS | 1 | PHASE2 | TP-05 |
| Moderna, Inc. | MRNA | 1 | PHASE2 | mRNA-1982 |
| AN2 Therapeutics, Inc. | ANTX | 1 | PHASE2 | Epetraborole |
| Emergent BioSolutions Inc. | EBS | 4 | - | AIGIV/kg |
| Phathom Pharmaceuticals, Inc. | PHAT | 1 | - | Vonoprazan |
VH4367310 is an investigational small molecule drug being developed by GSK plc for HIV infections. It is in Phase 1 clinical development and is being studied in healthy adult volunteers to assess its pharmacokinetics, safety, and tolerability. It has not been established as an approved treatment.
VH4367310 is being studied for HIV infections as an investigational small molecule therapeutic. Its clinical program is at the Phase 1 stage, focused on early pharmacokinetic, safety, and tolerability evaluation in healthy adult participants rather than on confirmed treatment use in patients.
VH4367310 is being developed by GSK plc, which trades under the ticker GSK. GSK is the sponsor of the Phase 1 program evaluating the compound in HIV infections, with the clinical work conducted in the United States.
VH4367310 is in Phase 1 clinical development. It is an investigational agent and is not approved for any use. The Phase 1 program is designed to investigate pharmacokinetics, safety, and tolerability in healthy adult participants.
VH4367310 is being studied in trial NCT07818915, titled A Study to Investigate Pharmacokinetics (PK), Safety, and Tolerability of VH4367310 in Healthy Adult Participants. This Phase 1 trial is currently recruiting, is placebo-controlled and double-blind, and plans to enroll 112 participants in the United States.
The Phase 1 trial NCT07818915 is a randomized, double-blind, placebo-controlled study in healthy adult volunteers aged 18 years and older, open to all sexes. It plans to enroll 112 participants across sites in the United States and is currently recruiting.